Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 1/20 | 0.33 |
| ▸ | UMPS | P11172 | 1/20 | 0.33 |
| ▸ | P2RY6 | Q15077 | 10/20 | 0.32 |
| ▸ | EIF4E | P06730 | 2/20 | 0.32 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15764141 | 1.00 | DNPH1 (0.33) | DNPH1UMPSP2RY6EIF4EP2RY14 | |
| SCHEMBL16597025 | 1.00 | DNPH1 (0.33) | DNPH1UMPSP2RY6EIF4EP2RY14 | |
| SCHEMBL16479392 | 1.00 | DNPH1 (0.33) | DNPH1UMPSP2RY6EIF4EP2RY14 | |
| SCHEMBL17703443 | 0.93 | DNPH1 (0.33) | DNPH1UMPSP2RY6EIF4EP2RY14 | |
| SCHEMBL17277059 | 0.89 | P2RY6 (0.33) | DNPH1UMPSP2RY6EIF4EP2RY14 | |
| SCHEMBL14930934 | 0.88 | DNPH1 (0.34) | DNPH1UMPSP2RY6EIF4EP2RY14 | |
| SCHEMBL18844822 | 0.87 | P2RY6 (0.34) | DNPH1UMPSP2RY6EIF4EP2RY14 | |
| SCHEMBL14948855 | 0.87 | DNPH1 (0.33) | DNPH1UMPSP2RY6EIF4EP2RY14 | |
| SCHEMBL15870442 | 0.87 | P2RY6 (0.34) | DNPH1UMPSP2RY6EIF4EP2RY14 | |
| SCHEMBL15250721 | 0.87 | P2RY6 (0.34) | DNPH1UMPSP2RY6EIF4EP2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158385-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158385-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | POLRMT, POLN, PHAX | DNPH1 3443/4885UMPS 1052/4885P2RY6 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.